DE69232699T2 - Über chirale phosphoratome gebundene oligonukleotide - Google Patents
Über chirale phosphoratome gebundene oligonukleotideInfo
- Publication number
- DE69232699T2 DE69232699T2 DE69232699T DE69232699T DE69232699T2 DE 69232699 T2 DE69232699 T2 DE 69232699T2 DE 69232699 T DE69232699 T DE 69232699T DE 69232699 T DE69232699 T DE 69232699T DE 69232699 T2 DE69232699 T2 DE 69232699T2
- Authority
- DE
- Germany
- Prior art keywords
- oligonucleotide
- group
- chiral
- substituted
- linkages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 292
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract description 139
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims abstract description 76
- -1 alkylphosphonate anion Chemical class 0.000 claims abstract description 58
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims abstract description 30
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims abstract description 25
- 230000000269 nucleophilic effect Effects 0.000 claims abstract description 11
- 238000010348 incorporation Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 103
- 238000000034 method Methods 0.000 claims description 100
- 239000002773 nucleotide Substances 0.000 claims description 78
- 125000003729 nucleotide group Chemical group 0.000 claims description 74
- 239000002777 nucleoside Substances 0.000 claims description 72
- 229910019142 PO4 Inorganic materials 0.000 claims description 57
- 239000010452 phosphate Substances 0.000 claims description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- 125000003835 nucleoside group Chemical group 0.000 claims description 48
- 230000000903 blocking effect Effects 0.000 claims description 44
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 33
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 28
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 27
- 229910052698 phosphorus Inorganic materials 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- 239000011574 phosphorus Substances 0.000 claims description 19
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 17
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 17
- 239000001226 triphosphate Substances 0.000 claims description 16
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 15
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- 230000002255 enzymatic effect Effects 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 12
- 235000011178 triphosphate Nutrition 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 5
- 229910004679 ONO2 Inorganic materials 0.000 claims description 5
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 5
- 229910021645 metal ion Inorganic materials 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 5
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 4
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 241000025769 Mucor luteus Species 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- OGBAQIDQMBHMAQ-UHFFFAOYSA-N bromo-chloro-fluoro-lambda3-iodane Chemical compound FI(Cl)Br OGBAQIDQMBHMAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 claims description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 claims description 2
- 241001515965 unidentified phage Species 0.000 claims description 2
- 101100311330 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap56 gene Proteins 0.000 claims 2
- 101150018444 sub2 gene Proteins 0.000 claims 2
- 108010037936 CCCGGG-specific type II deoxyribonucleases Proteins 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- OHKKJVUPYWMATB-UHFFFAOYSA-M [F-].[Mg+]C Chemical compound [F-].[Mg+]C OHKKJVUPYWMATB-UHFFFAOYSA-M 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 abstract description 27
- 235000000346 sugar Nutrition 0.000 abstract description 27
- 238000006243 chemical reaction Methods 0.000 abstract description 17
- 230000000707 stereoselective effect Effects 0.000 abstract description 10
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract description 6
- 239000000376 reactant Substances 0.000 abstract 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 44
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 34
- 235000021317 phosphate Nutrition 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 238000003786 synthesis reaction Methods 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 29
- 125000000217 alkyl group Chemical group 0.000 description 28
- 101710163270 Nuclease Proteins 0.000 description 24
- 229940104302 cytosine Drugs 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 229960000643 adenine Drugs 0.000 description 18
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 18
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 17
- 229930024421 Adenine Natural products 0.000 description 17
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 17
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 17
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 16
- 238000007792 addition Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 102100034343 Integrase Human genes 0.000 description 14
- 101710203526 Integrase Proteins 0.000 description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 12
- 230000008878 coupling Effects 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 229940035893 uracil Drugs 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 150000001450 anions Chemical class 0.000 description 10
- 125000002837 carbocyclic group Chemical group 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 239000005289 controlled pore glass Substances 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical class ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 229940113082 thymine Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 150000001449 anionic compounds Chemical class 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 229920002401 polyacrylamide Polymers 0.000 description 7
- 229940104230 thymidine Drugs 0.000 description 7
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 229920001519 homopolymer Polymers 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000004437 phosphorous atom Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 229940029575 guanosine Drugs 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108020004394 Complementary RNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- JCSNHEYOIASGKU-BWZBUEFSSA-N anhydrothymidine Chemical compound C1[C@H]2OC3=NC(=O)C(C)=CN3[C@@H]1O[C@@H]2CO JCSNHEYOIASGKU-BWZBUEFSSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001293 nucleolytic effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 125000005309 thioalkoxy group Chemical group 0.000 description 3
- WQYSXVGEZYESBR-UHFFFAOYSA-N thiophosphoryl chloride Chemical compound ClP(Cl)(Cl)=S WQYSXVGEZYESBR-UHFFFAOYSA-N 0.000 description 3
- TXWHPSZYRUHEGT-FTWQFJAYSA-N (2r,3r,4r,5r)-2-(2-amino-6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(N)=NC(Cl)=C2N=CN1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O TXWHPSZYRUHEGT-FTWQFJAYSA-N 0.000 description 2
- QCDAWXDDXYQEJJ-GQTRHBFLSA-N (2r,3s,4r,5r)-2-(6-aminopurin-9-yl)-4-fluoro-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](F)[C@H]1O QCDAWXDDXYQEJJ-GQTRHBFLSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PXBUCIJWSA-N 1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PXBUCIJWSA-N 0.000 description 2
- POFFHRCLHRQYTG-UHFFFAOYSA-N 2-[chloro(methyl)phosphoryl]oxy-2-methylpropane Chemical compound CC(C)(C)OP(C)(Cl)=O POFFHRCLHRQYTG-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-FTWQFJAYSA-N 2-amino-9-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O NYHBQMYGNKIUIF-FTWQFJAYSA-N 0.000 description 2
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KNFUADSATLYNGW-UHFFFAOYSA-N NP(O)(O)=O.NP(O)(O)=O.NP(O)(O)=O.P.P Chemical compound NP(O)(O)=O.NP(O)(O)=O.NP(O)(O)=O.P.P KNFUADSATLYNGW-UHFFFAOYSA-N 0.000 description 2
- QJGNOTPVMRULIG-UHFFFAOYSA-N NP(O)(O)=O.OP(O)(O)=O Chemical group NP(O)(O)=O.OP(O)(O)=O QJGNOTPVMRULIG-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000005122 aminoalkylamino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006140 methanolysis reaction Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GUCMSLDJFPHTIR-ABYLEIOUSA-N (2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-phenylmethoxyoxolan-3-ol Chemical compound O([C@@H]1[C@@H](O)[C@@H](CO)O[C@H]1N1C=2N=CN=C(C=2N=C1)N)CC1=CC=CC=C1 GUCMSLDJFPHTIR-ABYLEIOUSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-FTWQFJAYSA-N (2r,3r,4r,5r)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O ZDTFMPXQUSBYRL-FTWQFJAYSA-N 0.000 description 1
- LSTPFNJCTUEQDF-QRKAXHLRSA-N (2r,3s,4r,5r)-2-(6-aminopurin-9-yl)-4-ethylsulfanyl-5-(hydroxymethyl)oxolan-3-ol Chemical compound O[C@@H]1[C@@H](SCC)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LSTPFNJCTUEQDF-QRKAXHLRSA-N 0.000 description 1
- DHZCVEDTDMGIHQ-UHFFFAOYSA-N 1-(1-hydroxyethylsulfanyl)ethanol Chemical compound CC(O)SC(C)O DHZCVEDTDMGIHQ-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-JVZYCSMKSA-N 1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JVZYCSMKSA-N 0.000 description 1
- RHYWJBFVIQZQQA-XLPZGREQSA-N 1-[(2r,4s,5r)-5-(hydroxymethyl)-4-iodooxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](I)C1 RHYWJBFVIQZQQA-XLPZGREQSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- HOPIOIXCTXTMOG-UHFFFAOYSA-N 103769-63-7 Chemical class C1=CC=C2C3=CC=C(N=C4C(N=CO4)=C4)C4=C3NC2=C1 HOPIOIXCTXTMOG-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- VKXYEVRDQVTHAB-UHFFFAOYSA-N 2,6-diamino-7,9-dihydropurine-8-thione Chemical compound NC1=NC(N)=C2NC(=S)NC2=N1 VKXYEVRDQVTHAB-UHFFFAOYSA-N 0.000 description 1
- AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical compound C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- SIJAIGVOSYVMBX-UHFFFAOYSA-N 2-[chloro(methoxy)phosphoryl]oxy-2-methylpropane Chemical compound COP(Cl)(=O)OC(C)(C)C SIJAIGVOSYVMBX-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OTDJAMXESTUWLO-FTWQFJAYSA-N 2-amino-9-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OTDJAMXESTUWLO-FTWQFJAYSA-N 0.000 description 1
- VDOWHLFGBWKXJC-AYQXTPAHSA-N 2-amino-9-[(2r,3s,4r,5r)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@H](F)[C@H]1O VDOWHLFGBWKXJC-AYQXTPAHSA-N 0.000 description 1
- OTKJCBNXKGXIMU-UHFFFAOYSA-N 2-dichlorophosphoryloxy-2-methylpropane Chemical compound CC(C)(C)OP(Cl)(Cl)=O OTKJCBNXKGXIMU-UHFFFAOYSA-N 0.000 description 1
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- PHIYHIOQVWTXII-UHFFFAOYSA-N 3-amino-1-phenylpropan-1-ol Chemical compound NCCC(O)C1=CC=CC=C1 PHIYHIOQVWTXII-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- NIGDWBHWHVHOAD-UHFFFAOYSA-N 4,6-dichloropyrimidin-5-amine Chemical compound NC1=C(Cl)N=CN=C1Cl NIGDWBHWHVHOAD-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JVZYCSMKSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JVZYCSMKSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PXBUCIJWSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-PXBUCIJWSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- PTJWIQPHWPFNBW-JFRCYRBUSA-N 5-[(3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidine-2,4-dione Chemical compound C1([C@H](O)[C@@H](O)[C@H](O1)CO)C=1C(NC(NC=1)=O)=O PTJWIQPHWPFNBW-JFRCYRBUSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- BHVOFCPOXNYVCE-UHFFFAOYSA-N 6-amino-7,9-dihydropurine-8-thione Chemical compound NC1=NC=NC2=C1NC(=S)N2 BHVOFCPOXNYVCE-UHFFFAOYSA-N 0.000 description 1
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 1
- UGQMRVRMYYASKQ-GAWUUDPSSA-N 9-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O[C@@H]1[C@@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-GAWUUDPSSA-N 0.000 description 1
- ULXUKKMJONSWOY-QJPTWQEYSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-(3-imidazol-1-ylpropylamino)-3h-purin-6-one Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(NCCCN2C=NC=C2)NC2=O)=C2N=C1 ULXUKKMJONSWOY-QJPTWQEYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- OIRDTQYFTABQOQ-YTXCHSKXSA-N 9β-D-Xylosyladenine Chemical compound C1=NC=2C(N)=NC=NC=2N1C1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-YTXCHSKXSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101000595698 Candida albicans Tubulin beta chain Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical class C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010011356 Nucleoside phosphotransferase Proteins 0.000 description 1
- WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical group O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000006778 Pummerer Sulfoxide rearrangement reaction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- CILSTBQZISAPNO-LKZJOZGTSA-N [(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-trityloxy-2-(trityloxymethyl)oxolan-3-yl] methanesulfonate Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)OS(=O)(=O)C)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CILSTBQZISAPNO-LKZJOZGTSA-N 0.000 description 1
- IQYYKHOEPPPWKS-AAVRWANBSA-N [(2r,3r,4s,5s)-3,4-diacetyloxy-5-(7h-purin-2-yl)oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1C1=NC=C(NC=N2)C2=N1 IQYYKHOEPPPWKS-AAVRWANBSA-N 0.000 description 1
- FZGRVVNNENJDMC-WOUKDFQISA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methyl acetate Chemical compound O[C@@H]1[C@H](O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC=NC(O)=C2N=C1 FZGRVVNNENJDMC-WOUKDFQISA-N 0.000 description 1
- MRELHLHKFPLDIX-IDTAVKCVSA-N [(2r,3s,4r,5r)-3-acetyloxy-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methyl acetate Chemical compound O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MRELHLHKFPLDIX-IDTAVKCVSA-N 0.000 description 1
- RBQSYLJOONFNCY-NMFUWQPSSA-N [(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O[C@@H]1CO RBQSYLJOONFNCY-NMFUWQPSSA-N 0.000 description 1
- FZDNRNDYDNTDTI-ZFHGCVPZSA-N [(2r,3s,4s,5r)-4-acetyloxy-3-chloro-5-[6-(2,2-dimethylpropanoylamino)purin-9-yl]oxolan-2-yl]methyl 2,2-dimethylpropanoate Chemical compound CC(=O)O[C@@H]1[C@@H](Cl)[C@@H](COC(=O)C(C)(C)C)O[C@H]1N1C2=NC=NC(NC(=O)C(C)(C)C)=C2N=C1 FZDNRNDYDNTDTI-ZFHGCVPZSA-N 0.000 description 1
- SRIFAQOGQOLHIQ-SZRLZVLASA-N [(2r,3s,4s,5r)-4-acetyloxy-5-(6-aminopurin-9-yl)-3-bromooxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](Br)[C@@H](COC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SRIFAQOGQOLHIQ-SZRLZVLASA-N 0.000 description 1
- FUTVTSDLQPMPRT-DJLDLDEBSA-N [(2r,3s,5r)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] methanesulfonate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OS(C)(=O)=O)C1 FUTVTSDLQPMPRT-DJLDLDEBSA-N 0.000 description 1
- NLAIOTWSOVURMN-OYUWMTPXSA-N [(2r,3s,5r)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2-(trityloxymethyl)oxolan-3-yl] methanesulfonate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)[C@@H](OS(C)(=O)=O)C1 NLAIOTWSOVURMN-OYUWMTPXSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-MVKANHKCSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxy(32P)phosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO[32P](O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-MVKANHKCSA-N 0.000 description 1
- XDMOACSEVLCDIX-UHFFFAOYSA-N [amino-(amino-azido-carboxy-cyano-nitro-lambda6-sulfanyl)sulfanyl-azido-cyano-nitro-lambda6-sulfanyl]formic acid Chemical class NS([N+](=O)[O-])(C#N)(C(=O)O)(N=[N+]=[N-])SS(N)(N=[N+]=[N-])(C(=O)O)(C#N)[N+](=O)[O-] XDMOACSEVLCDIX-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical class C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- NPTIAZRCRQOIJR-UHFFFAOYSA-N chloro-methyl-[(2-methylpropan-2-yl)oxy]-sulfanylidene-$l^{5}-phosphane Chemical compound CC(C)(C)OP(C)(Cl)=S NPTIAZRCRQOIJR-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- NLIHPCYXRYQPSD-BAJZRUMYSA-N cordycepin triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C[C@H]1O NLIHPCYXRYQPSD-BAJZRUMYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- URMKGIFOBPAYHC-UHFFFAOYSA-N dichloro-[(2-methylpropan-2-yl)oxy]-sulfanylidene-$l^{5}-phosphane Chemical compound CC(C)(C)OP(Cl)(Cl)=S URMKGIFOBPAYHC-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical class CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- RZZCIBFHZYEENN-UHFFFAOYSA-N n-(6-chloro-7h-purin-2-yl)acetamide Chemical class CC(=O)NC1=NC(Cl)=C2NC=NC2=N1 RZZCIBFHZYEENN-UHFFFAOYSA-N 0.000 description 1
- FTHDBQFEMBNGJU-UHFFFAOYSA-N n-[chloro-[(2-methylpropan-2-yl)oxy]phosphoryl]-2-ethoxyethanamine Chemical compound CCOCCNP(Cl)(=O)OC(C)(C)C FTHDBQFEMBNGJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical class [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000006245 phosphate protecting group Chemical group 0.000 description 1
- 125000002743 phosphorus functional group Chemical group 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003220 pyrenes Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 125000002652 ribonucleotide group Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- QSUJAUYJBJRLKV-UHFFFAOYSA-M tetraethylazanium;fluoride Chemical compound [F-].CC[N+](CC)(CC)CC QSUJAUYJBJRLKV-UHFFFAOYSA-M 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 238000006863 thiophosphorylation reaction Methods 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- YZVRVDPMGYFCGL-UHFFFAOYSA-N triacetyloxysilyl acetate Chemical compound CC(=O)O[Si](OC(C)=O)(OC(C)=O)OC(C)=O YZVRVDPMGYFCGL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (37)
1. Sequenzspezifisches Oligonukleotid, das mindestes 10 Einheiten
aufweist, die miteinander verbunden und komplementär zu mindestens
einem Teil einer Sequenz einer Target-RNA oder -DNA sind, wobei
mindestens drei der Nukleosid-Einheiten durch entweder im
wesentlichen ausschließlich Rp- oder im wesentlichen ausschließlich Sp-
Phosphorthioat, -Alkylphosphonat, -Phosphotriester oder -Phosporamidat
miteinander verbunden sind, mit der Maßgabe, daß, wenn das
Oligonukleotid durch ausschließlich Phosphorthioat-Verknüpfungen
miteinander verbunden ist, dann das Oligonukleotid weniger als alle
Nukleosid-Einheiten miteinander durch entweder ausschließlich Rp- oder
ausschließlich Sp-Verknüpfungen verbunden aufweist.
2. Oligonukleotid nach Anspruch 1, wobei die Phosphat-Verknüpfungen aus
der Gruppe, bestehend aus chiralem Sp-Phosphorthioat, chiralem Rp-
Phosphorthioat, chiralem Sp-Alkylphosphonat, chiralem Rp-
Alkylphosphonat, chiralem Sp-Phosphoamidat, chiralem Rp-
Phosphoamidat, chiralem Sp-Phosphotriester und chiralem Rp-
Phosphotriester, ausgewählt sind.
3. Oligonukleotid, umfassend mindestens 10 Nukleosid-Einheiten, die
miteinander durch Phosphat-Verknüpfungen verbunden sind, wobei:
mindestens eine der Nukleosid-Einheiten eine nicht-natürlich
vorkommende Nukleosid-Einheit ist, die an der 2'-Position einen
Substituenten aufweist, der aus der Gruppe, bestehend aus OH, C&sub1;&submin;&sub1;&sub2;
Alkyl, substituiertem C&sub1;&submin;&sub1;&sub2; Alkyl, F, Cl, Br, CN, CF&sub3;, OCF&sub3;, OCN, O-Alkyl,
substituiertem O-Alkyl, S-Alkyl, substituiertem S-Alkyl, SOMe, SO&sub2;Me,
ONO&sub2;, NO&sub2;, N&sub3;, NH&sub2;, NH-Alkyl, substituiertem NH-Alkyl, OCH&sub2;CH=CH&sub2;,
OCH=CH&sub2;, OCH&sub2;CCH, OCCH, Aralkyl, Heteroaralkyl, Heterocycloalkyl,
Poly-Alkylamino, substituiertem Silyl, einem RNA-spaltenden Rest, einer
Gruppe, welche die pharmakodynamischen Eigenschaften eines
Oligonukleotids verbessert, oder einer Gruppe, welche die
pharmakokinetischen Eigenschaften eines Oligonukleotids verbessert,
ausgewählt ist; und
mindestens zwei der Einheiten durch chirale Phosphat-Verknüpfungen
verbunden sind.
4. Oligonukleotid nach Anspruch 3, worin die chiralen Phosphat-
Verknüpfungen aus der Gruppe, bestehend aus chiralem Sp-
Phosphorthioat, chiralem Rp-Phosphorthioat, chiralem Sp-
Alkylphosphonat, chiralem Rp-Alkylphosphonat, chiralem Sp-
Phosphoamidat, chiralem Rp-Phosphoamidat, chiralem Sp-
Phosphotriester und chiralem Rp-Phosphotriester, ausgewählt sind.
5. Oligonukleotid nach Anspruch 3, worin jede der Phosphat-
Verknüpfungen eine chirale Phospat-Verknüpfung ist.
6. Oligonukleotid gemäß irgendeinem der Ansprüche 1 bis 5, umfassend
eine Vielzahl von Nukleosid-Einheiten, die miteinander durch
ausschließlich Sp-Phosphotriester-Verknüpfungen oder ausschließlich
Rp-Phosphotriester-Verknüpfungen verbunden sind.
7. Oligonukleotid gemäß irgendeinem der Ansprüche 1 bis 5, umfassend
eine Vielzahl von Nukleosid-Einheiten, die miteinander durch
ausschließlich Sp-Phosphoramidat-Verknüpfungen oder ausschließlich
Rp-Phosphoramidat-Verknüpfungen verbunden sind.
8. Oligonukleotid gemäß irgendeinem der Ansprüche 1 bis 5, umfassend
mindestens 10 Nukleosid-Einheiten, die miteinander durch ausschließlich
Sp-Alkylphosphonat-Verknüpfungen oder ausschließlich Rp-
Alkylphosphonat-Verknüpfungen verbunden sind.
9. Oligonukleotid nach Anspruch 8, wobei die Alkylphosphonat-
Verknüpfungen Methylphosphonat-Verknüpfungen sind.
10. Oligonukleotid gemäß irgendeinem der Ansprüche 1 bis 9 für die
Verwendung in der Medizin.
11. Verfahren zum Synthetisieren des Oligonukleotids nach Anspruch 1,
umfassend die Schritte:
(a) Auswählen eines ersten Synthons mit der Struktur:
(b) Auswählen eines zweiten Synthons mit der Struktur:
(c) Inkontaktbringen des zweiten Synthons mit dem ersten Synthon in
der Gegenwart einer Base, um einen nukleophilen Angriff eines 5'-
Phosphats des ersten Synthons an einer 3'-Position des zweiten
Synthons zu bewirken, unter Erhalten eines neuen ersten Synthons über
eine Inversion der Konfiguration an der 3'-Position des zweiten Synthons;
und
(d) Behandeln des neuen ersten Synthons mit einem Reagens zur
Entfernung der blockierenden Gruppe RF;
wobei:
Q O oder CH&sub2; ist;
RD Methyl, O-Alkyl, S-Alkyl, Amino oder substituiertes Amino ist;
RE O oder S ist;
RF H oder eine labile blockierende Gruppe ist;
RX H, OH oder eine Zucker-derivatisierende Gruppe ist;
BX eine natürlich vorkommende oder synthetische Nukleosidbase oder
blockierte Nukleosidbase ist;
L eine Abgangsgruppe ist oder L und BX zusammen ein 2-3'- oder 6-3'-
Pyrimidin- oder 8-3'-Purin-Cyclo-Nukleosid sind; und
Y eine stabile blockierende Gruppe, ein Festkörperträger, ein Nukleotid
auf einem Festkörperträger oder ein Oligonukleotid auf einem
Festkörperträger ist.
12. Verfahren nach Anspruch 11, wobei L aus der Gruppe, bestehend aus
Halogen, Alkylsulfonyl, substituiertem Alkylsulfonyl, Arylsulfonyl,
substituiertem Arylsulfonyl, Heterocyclosulfonyl und Trichloracetimidat,
ausgewählt ist.
13. Verfahren nach Anspruch 11, wobei L aus der Gruppe, bestehend aus
Chlor, Fluor, Brom, Iod, p-(2,4-Dinitroanilin)-benzolsulfonyl,
Benzolsulfonyl, Methylsulfonyl (Mesylat), p-Methylbenzolsulfonyl
(Tosylat), p-Brombenzolsulfonyl, Trifluormethylsulfonyl (Triflat),
Trichloracetimidat, Acyloxy, 2,2,2-Trifluorethansulfonyl, Imidazolsulfonyl
und 2,4,6-Trichlorphenyl, ausgewählt ist.
14. Verfahren nach Anspruch 11, wobei die Base aus der Gruppe,
bestehend aus Natriumhydrid, Methylmagnesiumchlorid, t-
Butylmagnesiumchlorid und Methylmagnesiumfluorid, ausgewählt ist.
15. Verfahren nach Anspruch 11, wobei RF eine säurelabile blockierende
Gruppe ist.
16. Verfahren nach Anspruch 11, wobei Y eine hydrogenolyseempfindliche
blockierende Gruppe ist.
17. Verfahren nach Anspruch 11, wobei RF aus der Gruppe, bestehend aus
t-Butyl, Dimethoxytrityl und Tetrahydropyranyl, ausgewählt ist.
18. Verfahren nach Anspruch 11, wobei das neue erste Synthon die Struktur:
aufweist.
19. Verfahren nach Anspruch 11, ferner umfassend das Inkontaktbringen
des ersten Synthons mit der Base in einem Lösungsmittel, das aus der
Gruppe, bestehend aus Acetonitril, Tetrahydrofuran und Dioxan,
ausgewählt ist.
20. Verfahren nach Anspruch 11, wobei das Reagens, das zum Entfernen
der blockierenden Gruppe RF verwendet wird, eine Säure ist, die aus der
Gruppe, bestehend aus Trichloressigsäure, Essigsäure und
Trifluormethansulfonsäure, ausgewählt ist.
21. Verbindung mit der Struktur:
wobei:
Q O oder CH&sub2; ist;
RD O, S, Methyl, O-Alkyl, S-Alkyl, Amino oder substituiertes Amino ist;
RE O oder S ist;
RF H oder eine blockierende Gruppe ist;
RX H, OH oder eine Zucker-derivatisierende Gruppe ist;
BX eine Nukleosidbase oder eine blockierte Nukleosidbase ist; und
L eine Abgangsgruppe ist oder L und BX zusammen ein 2-3'- oder 6-3'-
Pyrimidin- oder 8-3'-Purin-Cyclo-Nukleosid sind.
22. Verbindung nach Anspruch 21, wobei L aus der Gruppe, bestehend aus
Halogen, Alkylsulfonyl, substituiertem Alkylsulfonyl, Arylsulfonyl,
substituiertem Arylsulfonyl, Heterocyclosulfonyl und Trichloracetimidat,
ausgewählt ist.
23. Verbindung nach Anspruch 21, wobei L aus der Gruppe, bestehend aus
Chlor, Fluor, Brom, Iod, p-(2,4-Dinitroanilin)-benzolsulfonyl,
Benzolsulfonyl, Methylsulfonyl (Mesylat), p-Methylbenzolsulfonyl
(Tosylat), p-Brombenzolsulfonyl, Trifluormethylsulfonyl (Triflat),
Trichloracetimidat, Acyloxy, 2,2,2-Trifluorethansulfonyl, Imidazolsulfonyl
und 2,4,6-Trichlorphenyl, ausgewählt ist.
24. Verbindung nach Anspruch 21, wobei RX H, OH, Alkyl, Alkenyl, Alkinyl,
substituiertes Alkyl, Alkenyl, Alkinyl, F, Cl, Br, CN, CF&sub3;, OCF&sub3;, OCN, O-
Alkyl, O-Alkenyl, O-Alkinyl, substituiertes O-Alkyl, substituiertes O-
Alkenyl, substituiertes O-Alkinyl, S-Alkyl, S-Alkenyl, S-Alkinyl,
substituiertes S-Alkyl, substituiertes S-Alkenyl, substituiertes S-Alkinyl,
SOMe, SO&sub2;Me, ONO&sub2;, NO&sub2;, N&sub3;, NH&sub2;, NH-Alkyl, NH-Alkenyl, NH-Alkinyl,
substituiertes NH-Alkyl, substituiertes NH-Alkenyl, substituiertes NH-
Alkinyl, OCH&sub2;CH=CH&sub2;, OCH=CH&sub2;, OCH&sub2;CCH, OCCH, Aralkyl, Aralkenyl,
Aralkinyl, Heteroaralkyl, Heteroaralkenyl, Heteroaralkinyl,
Heterocycloalkyl, Poly(alkylamino), substituiertes Silyl, ein RNA-
spaltender Rest, eine Gruppe, welche die pharmakodynamischen
Eigenschaften eines Oligonukleotids verbessert, oder eine Gruppe,
welche die pharmakokinetischen Eigenschaften eines Oligonukleotids
verbessert, ist.
25. Verbindung nach Anspruch 21, wobei RF aus der Gruppe, bestehend aus
H, t-Butyl, Dimethoxytrityl und Tetrahydropyranyl, ausgewählt ist.
26. Verbindung nach Anspruch 21, wobei Q O ist.
27. Verbindung nach Anspruch 21 mit Sp-Stereochemie.
28. Verbindung nach Anspruch 21 mit Rp-Stereochemie.
29. Enzymatisches Verfahren zum Synthetisieren des Oligonukleotids nach
Anspruch 2, wobei das Oligonukleotid mindestes 10 Nukleosid-Einheiten
aufweist, die durch entweder im wesentlichen ausschließlich Sp- oder im
wesentlichen ausschließlich Rp-Phosphor-Interzucker-Verknüpfungen
miteinander verbunden sind, umfassend die Schritte:
Kombinieren eines Sequenzprimers und eines Templates;
Hinzugeben eines Überschusses aller vier Nukleosid-5'-O-Triphosphate,
die einen gewünschten 5'-Phosphat-Rest aufweisen; wobei das
Triphosphat eines der im wesentlichen ausschließlich Rp- oder
ausschließlich Sp-Triphosphate ist;
Hinzugeben von Polymerase, die wirksam für das Verlängern des
Primers ist, um ein Oligonukleotid zu bilden, das komplementär zu dem
Templat ist; und
Disassoziieren des entstehenden Oligonukleotids von dem Primer und
von dem Templat.
30. Verfahren nach Anspruch 29, wobei mindestens ein Schritt eine Vielzahl
von Malen wiederholt wird, die ausreicht, um die Ausbeute des
sequenzspezifischen Phosphorthioat-Oligonukleotids zu fördern.
31. Enzymatisches Verfahren zum Synthetisieren des Oligonukleotids nach
Anspruch 2, wobei das Oligonukleotid mindestes 10 Nukleosid-Einheiten
aufweist, die durch entweder im wesentlichen ausschließlich Sp-
Phosphor-Interzucker-Verknüpfungen oder im wesentlichen
ausschließlich Rp-Phosphor-Interzucker-Verknüpfungen miteinander
verbunden sind, umfassend die Schritte:
Vereinigen eines Sequenzprimers und eines Templates;
Hinzugeben eines Überschusses einer racemischen Mischung aller vier
Nukleosid-5'-O-(Triphosphate), die einen gewünschten 5'-Phosphat-Rest
aufweisen;
Hinzugeben eines ausgewählten Metallions, das wirksam ist, die
bevorzugte Einfügung von entweder Rp- oder Sp-Triphosphaten zu
fördern;
Hinzugeben von Polymerase, die wirksam für das Verlängern des
Primers ist, um ein Oligonukleotid zu bilden, das komplementär zu dem
Templat ist; und
Disassoziieren des entstehenden Oligonukleotids von dem Primer und
von dem Templat.
32. Verfahren nach Anspruch 31, wobei das Metallion Magnesium ist.
33. Verfahren nach Anspruch 31, wobei das Metallion Mangan ist.
34. Verfahren nach Anspruch 29 oder Anspruch 31, ferner umfassend die
Schritte:
Prähybridisieren des Templats und des Primers durch Erwärmen des
Templats und des Primers miteinander; und
Abkühlen der Templat-und-Primer-Mischung vor der Zugabe der
Triphosphate.
35. Verfahren nach Anspruch 29 oder Anspruch 31, wobei die Polymerase
T7-DNA-Polymerase, modifizierte T7-DNA-Polymerase I, T7-RNA-
Polymerase, T4-Bakteriophagen-Polymerase, modifizierte T4-DNA-
Polymerase, M. luteus-Polymerase, DNA-poly-Klenow-Fragment-
Polymerase, E. coli-RNA-Polymerase oder E. coli-DNA-Polymerase ist.
36. Verfahren nach Anspruch 29 oder Anspruch 31, wobei die
Disassozierung von dem Primer mittels Pst-1-Restriktions-Endonuklease,
BamH1-Restriktions-Endonuklease, SmaI-Restriktions-Endonuklease
oder HinD-III-Restriktions-Endonuklease erreicht wird.
37. Verfahren nach Anspruch 29 oder Anspruch 31, wobei die
Disassozierung durch DNAse-I-Verdauung erreicht wird.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/777,670 US5212295A (en) | 1990-01-11 | 1991-10-15 | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US77700791A | 1991-10-16 | 1991-10-16 | |
PCT/US1992/008797 WO1993008296A1 (en) | 1991-10-15 | 1992-10-14 | Oligonucleotides having chiral phosphorus linkages |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69232699D1 DE69232699D1 (de) | 2002-08-29 |
DE69232699T2 true DE69232699T2 (de) | 2003-02-06 |
Family
ID=27119268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69232699T Expired - Lifetime DE69232699T2 (de) | 1991-10-15 | 1992-10-14 | Über chirale phosphoratome gebundene oligonukleotide |
Country Status (8)
Country | Link |
---|---|
US (1) | US6699979B2 (de) |
EP (1) | EP0655088B1 (de) |
JP (1) | JP2693643B2 (de) |
AT (1) | ATE221127T1 (de) |
AU (1) | AU2874892A (de) |
CA (1) | CA2121144C (de) |
DE (1) | DE69232699T2 (de) |
WO (1) | WO1993008296A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US6001982A (en) * | 1993-07-29 | 1999-12-14 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
WO1996019572A1 (en) * | 1994-12-22 | 1996-06-27 | Hybridon, Inc. | Synthesis of stereospecific oligonucleotide phosphorothioates |
US5962674A (en) * | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
US6531589B1 (en) | 1995-06-01 | 2003-03-11 | Hybridon, Inc. | Base protecting groups and synthons for oligonucleotide synthesis |
US6140482A (en) * | 1995-06-01 | 2000-10-31 | Hybridon, Inc. | Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same |
WO1996039414A1 (en) * | 1995-06-01 | 1996-12-12 | Hybridon, Inc. | Novel base protecting groups for oligonucleotide synthesis |
JPH10510433A (ja) * | 1995-06-06 | 1998-10-13 | アイシス・ファーマシューティカルス・インコーポレーテッド | 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド |
US5739311A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases |
KR19990022596A (ko) * | 1995-06-07 | 1999-03-25 | 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 | 효소적으로 절단 가능한 주형 및 시발체 기제 올리고뉴클레오티드의 합성 |
US5932450A (en) * | 1995-06-07 | 1999-08-03 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using digestible templates |
US5652126A (en) * | 1995-06-07 | 1997-07-29 | Gen-Probe Incorporated | Use of restriction endonuclease sequences for cleaving phosphorothioate oligonucleotides |
US5916777A (en) * | 1995-06-07 | 1999-06-29 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using 3'-ribonucleotide primers |
WO1999005160A2 (en) * | 1997-07-25 | 1999-02-04 | Hybridon, Inc. | Oligonuclotides having 3' terminal stereospecific phosphorothioates |
US6867289B1 (en) * | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
WO2002092006A2 (en) * | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
US20030162190A1 (en) * | 2001-11-15 | 2003-08-28 | Gorenstein David G. | Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics |
CA2502610A1 (en) | 2002-10-16 | 2005-01-13 | Board Of Regents Of The University Of Texas System | Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries |
US20090186343A1 (en) * | 2003-01-28 | 2009-07-23 | Visigen Biotechnologies, Inc. | Methods for preparing modified biomolecules, modified biomolecules and methods for using same |
EP1635765B1 (de) | 2003-05-23 | 2013-07-17 | Board Of Regents, The University Of Texas System | Strukturbasiertes und kombinatorisch ausgewähltes oligonucleosid-phosphorothioat und phosphorodithioat aptamer targeting ap-1 transkriptionsfaktoren |
US7772390B1 (en) | 2006-07-18 | 2010-08-10 | The Regents Of The University Of California | Lipid mediated nucleic acid synthesis |
ES2911034T3 (es) | 2006-08-08 | 2022-05-17 | Univ Bonn Rheinische Friedrich Wilhelms | Estructura y uso de oligonucleótidos 5' fosfato |
US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
US20150025122A1 (en) * | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
JP2013198425A (ja) * | 2012-03-24 | 2013-10-03 | Kanagawa Univ | オリゴヌクレオチドの製造方法 |
CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
EP2872485B1 (de) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetrische hilfsgruppe |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
PT3094728T (pt) * | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
AU2016334232B2 (en) | 2015-10-09 | 2022-05-26 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506212A (en) | 1990-01-11 | 1996-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides with substantially chirally pure phosphorothioate linkages |
US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US5635488A (en) | 1991-10-15 | 1997-06-03 | Isis Pharmaceuticals, Inc. | Compounds having phosphorodithioate linkages of high chiral purity |
US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
US5620963A (en) | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
US5512668A (en) * | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
US5359052A (en) | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US5646267A (en) | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
US5607923A (en) | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
US5599797A (en) | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
DE69629112T2 (de) | 1995-05-26 | 2004-04-22 | Genta Inc., San Diego | Verfahren zur synthese von phosphororganischen verbindungen |
DE69622571T2 (de) | 1995-09-01 | 2003-03-27 | Polska Akademia Nauk- Centrum Badan Molekularnych I Makromolekularnych, Iodz | Zusammensetzungen und verfahrenen zur synthese von organophosphorus derivaten |
US5856465A (en) | 1996-05-24 | 1999-01-05 | Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych | Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives |
-
1992
- 1992-10-14 CA CA002121144A patent/CA2121144C/en not_active Expired - Fee Related
- 1992-10-14 DE DE69232699T patent/DE69232699T2/de not_active Expired - Lifetime
- 1992-10-14 AU AU28748/92A patent/AU2874892A/en not_active Abandoned
- 1992-10-14 AT AT92922127T patent/ATE221127T1/de not_active IP Right Cessation
- 1992-10-14 EP EP92922127A patent/EP0655088B1/de not_active Expired - Lifetime
- 1992-10-14 JP JP5507797A patent/JP2693643B2/ja not_active Expired - Lifetime
- 1992-10-14 WO PCT/US1992/008797 patent/WO1993008296A1/en active IP Right Grant
-
2002
- 2002-05-17 US US10/150,696 patent/US6699979B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6699979B2 (en) | 2004-03-02 |
CA2121144C (en) | 2001-07-31 |
EP0655088A4 (de) | 1996-01-10 |
JPH06511492A (ja) | 1994-12-22 |
AU2874892A (en) | 1993-05-21 |
JP2693643B2 (ja) | 1997-12-24 |
EP0655088A1 (de) | 1995-05-31 |
EP0655088B1 (de) | 2002-07-24 |
DE69232699D1 (de) | 2002-08-29 |
ATE221127T1 (de) | 2002-08-15 |
US20020137921A1 (en) | 2002-09-26 |
CA2121144A1 (en) | 1993-04-29 |
WO1993008296A1 (en) | 1993-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69232699T2 (de) | Über chirale phosphoratome gebundene oligonukleotide | |
US5852188A (en) | Oligonucleotides having chiral phosphorus linkages | |
US5212295A (en) | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | |
DE69729179T2 (de) | Lückenhaft Zucker-modifizierte Oligonukleotide | |
DE69331524T2 (de) | Verfahren zum spezifischen schneiden von rna-strängen | |
DE69126530T2 (de) | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren | |
US5506212A (en) | Oligonucleotides with substantially chirally pure phosphorothioate linkages | |
DE69133405T2 (de) | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression | |
DE69233599T2 (de) | Unterbrochene 2'-modifizierte Oligonukleotide | |
DE69319336T2 (de) | N-acylierte 2'-deoxycytidine für die oligonukleotid synthese | |
DE69133511T2 (de) | Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression | |
US5635488A (en) | Compounds having phosphorodithioate linkages of high chiral purity | |
US5661134A (en) | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity | |
EP1483280B1 (de) | Fluoreszente stickstoffbasen und nukleoside damit | |
US5587361A (en) | Oligonucleotides having phosphorothioate linkages of high chiral purity | |
US5599797A (en) | Oligonucleotides having phosphorothioate linkages of high chiral purity | |
US5607923A (en) | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity | |
DE69322640T2 (de) | Bindungskompetente oligomere, die 2',5'-bindungen enthalten | |
US8530640B2 (en) | Bicyclic cyclohexitol nucleic acid analogs | |
DE60038495T2 (de) | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung | |
US5576302A (en) | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity | |
US5620963A (en) | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity | |
JPH10510433A (ja) | 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド | |
DE69427705T2 (de) | Bor-cluster enthaltende nukleoside und oligonukleoside | |
DE69934227T2 (de) | Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |